Managing Partner, VRS (Valuation & Research Specialists)

VRS (Valuation & Research Specialists)

Financial analyst specializing on corporate valuation. Long-term experience in analyzing and valuing listed and non listed companies in a wide range of business sectors in Europe, North America and internationally. Some of the sectors covered are financial services, industrials, high technology and real estate. Certified Equity Analyst by the Hellenic Capital Market Commission, Greece. Member of the Hellenic Association of Certified Securities Analysts (HACSA), Greece. Associate Member of the Chartered Institute for Securities & Investment (CISI), UK.

Specialties: Applying methods in corporate valuation, developing valuation models and writing equity research and valuation reports. Consulting services to companies with regard to their valuation drivers and potential corporate value, utilized in corporate deals such as mergers, acquisitions and sale of businesses. Specialized financial translations.

Managing Partner

Valuation & Research Specialists (VRS) is a boutique financial advisor with more than 17 years of experience in Corporate Valuation and Finance, and a diversified client base including some of the largest Companies in Greece.

Since 2002, VRS has completed more than 200 engagements in the areas of business valuation and financial analysis for more than 100 clients in a wide range of industries.

VRS has been honored to work with small and large private and publicly traded companies in Europe and overseas.

Boutique Financial Advisor

Equity Bottom-Up

<ul><li>Net Sales decreased by 12.6% in FY2023 settling at EUR 62.3M (vs 70.7M in FY2022).</li><li>Part of this decrease can be attributed to the decreasing demand for sanitizing products (Covid-19).</li><li>However Gross profit increased by 12.6% from 13.873 in 9M2022 to 15.631 in 9M2023 due to a decrease in Raw Materials Costs, Cost of Energy, and lastly due to higher efficiency in the production.</li></ul>

Net Sales decreased by 12.6% in FY2023 settling at EUR 62.3M (vs 70.7M in FY2022).Part of this decrease can be attributed to the decreasing demand for sanitizing products (Covid-19).However Gross profit increased by 12.6% from 13.873 in 9M2022 to 15.631 in 9M2023 due to a decrease in Raw Materials Costs, Cost of Energy, and lastly due to higher efficiency in the production.

Papoutsanis S.a. - 9M-11M FY2023 Results Presentation